Severe Pulmonary Hypertension in Pregnancy Carries a High Maternal Mortality Risk

1. Severity and Prognosis

• A pulmonary artery systolic pressure of ≈121 mmHg in a pregnant woman defines severe, life‑threatening pulmonary hypertension and is associated with a 17 %–33 % maternal mortality risk, mandating urgent counseling for pregnancy termination and multidisciplinary care at a specialized center. 1
• Normal mean pulmonary artery pressure (mPAP) at rest is 14–20 mmHg; pulmonary hypertension is diagnosed when mPAP is ≥25 mmHg (older definition) or >20 mmHg (newer definition). [2][3]
• A pressure of ≈121 mmHg most likely reflects systolic pulmonary artery pressure, which is 4–5 times the upper limit of normal, indicating severe precapillary pulmonary hypertension. 2
• Pregnancy worsens pulmonary hypertension even when only moderate, due to decreased systemic vascular resistance and right‑ventricular volume overload. 1
• Maternal deaths most often occur in the late third trimester or the first months postpartum, driven by hypertensive crises, pulmonary embolism, or refractory right‑heart failure. 1

2. Differential Diagnosis (Etiologic Groups)

• Group 1 – Pulmonary Arterial Hypertension (PAH)
  
  • Idiopathic PAH, heritable/familial PAH, connective‑tissue‑disease‑associated PAH (e.g., systemic sclerosis, lupus), congenital heart disease with shunt (Eisenmenger syndrome), portal‑hypertension‑associated PAH, HIV‑associated PAH, and drug/toxin‑induced PAH (e.g., anorexigens, methamphetamines). [3][4][5][1]
• Group 2 – Pulmonary Hypertension Due to Left‑Heart Disease
  
  • Left‑ventricular systolic or diastolic dysfunction (including peripartum cardiomyopathy), left‑sided valvular disease (mitral/aortic stenosis or regurgitation), and congenital/acquired left‑heart inflow or outflow obstruction. [3][4]5
• Group 3 – Pulmonary Hypertension Due to Lung Disease
  
  • Chronic obstructive pulmonary disease, interstitial lung disease (e.g., sarcoidosis, idiopathic pulmonary fibrosis), and sleep‑disordered breathing (obstructive sleep apnea). [3][4]5
• Group 4 – Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
  
  • Prior pulmonary embolism or deep‑vein thrombosis, pregnancy‑related hypercoagulable state, and chronic organized thrombi detectable on V/Q scan or CT pulmonary angiography. [3][4]5
• Group 5 – Multifactorial/Unclear Mechanisms
  
  • Hematologic disorders (e.g., sickle‑cell disease), systemic disorders with vascular involvement (e.g., sarcoidosis), and metabolic disorders (e.g., thyroid disease). [3][4]

3. Diagnostic Work‑up

• Right‑heart catheterisation is mandatory for definitive diagnosis; diagnostic thresholds include mean PAP > 20 mmHg, pulmonary capillary wedge pressure ≤ 15 mmHg (confirming precapillary PH), and pulmonary vascular resistance > 3 Wood units. [3][4]5
• Transthoracic echocardiography provides an initial estimate of right‑ventricular function, tricuspid regurgitation severity, and pulmonary pressures, but catheterisation remains the gold standard. 5
• Ventilation/perfusion (V/Q) scan is essential to exclude CTEPH, revealing segmental perfusion defects when present. 5
• High‑resolution CT of the chest evaluates interstitial lung disease, emphysema, and pulmonary veno‑occlusive disease (ground‑glass opacities, septal thickening). 5
• Pulmonary function tests with DLCO typically show a reduced diffusing capacity (≈40 %–80 % of predicted) in PAH, aiding differentiation from obstructive or restrictive lung disease. 5
• Serologic panels (ANA, anti‑Scl‑70, anti‑centromere, anti‑RNP, rheumatoid factor) screen for connective‑tissue disease; HIV testing, liver‑function tests, and thyroid studies identify associated systemic conditions. 5
• Echocardiography with bubble study detects congenital shunts or left‑heart disease contributing to PH. [5][1]

4. Management Principles

4.1 Pregnancy Termination

• Immediate offer of pregnancy termination is recommended because of the 17 %–33 % maternal mortality risk, even when optimal care is available. 1
• Termination should be performed at a tertiary centre with expertise in PAH to manage anesthesia and hemodynamic instability. 1
• General anesthesia carries extreme risk; regional anesthesia is preferred whenever feasible. 1

4.2 Continuation of Pregnancy (if chosen)

• Urgent transfer to a specialised pulmonary‑hypertension centre with maternal‑fetal medicine, cardiology, and anesthesiology teams. 1
• Avoid systemic hypotension, hypoxia, and acidosis, which precipitate refractory right‑heart failure. 1
• Supplemental oxygen should be administered to any patient with hypoxemia. 1
• Intravenous prostacyclin or aerosolised iloprost may be used peripartum to improve hemodynamics. 1
• Anticoagulation (e.g., unfractionated or low‑molecular‑weight heparin) should be continued when indicated; warfarin is contraindicated in pregnancy. 1
• Teratogenic PAH therapies such as endothelin‑receptor antagonists (e.g., bosentan) must be avoided. 1

4.3 Common Pitfalls to Avoid

• Do not rely solely on echocardiography for therapeutic decisions; right‑heart catheterisation is required for accurate hemodynamic assessment. 5
• Stable‑appearing symptoms do not guarantee safety; rapid deterioration can occur even in minimally disabled patients. 1
• Routine use of Swan‑Ganz catheters is discouraged due to the risk of pulmonary‑artery rupture without proven benefit. 1
• Do not delay referral; late hospital admission is a recognized risk factor for maternal death. 1

Pulmonary Artery Pressure in Pregnancy

Defining Normal vs. Abnormal Pressures

• Normal mean pulmonary artery pressure (mPAP) remains 14-20 mmHg at rest in pregnant women with no underlying medical conditions, identical to non-pregnant individuals, as recommended by the American College of Radiology 6, 7
• The threshold for pulmonary hypertension does not change during pregnancy, with normal mPAP being 14-20 mmHg at rest, uncertain significance being 21-24 mmHg, and pulmonary hypertension being ≥25 mmHg (older definition) or >20 mmHg (newer definition) 6, 7, 8, 9, 10, 11

Critical Clinical Context for Pregnancy

• Pregnancy with pulmonary hypertension carries 17-33% maternal mortality in recent studies, according to the European Heart Journal 8, 9, 10, 11
• Even moderate pulmonary hypertension can worsen during pregnancy due to decreased systemic vascular resistance and right ventricular volume overload, as reported by the European Heart Journal 8, 9, 10, 11

Physiologic Changes to Consider

• Pregnancy induces substantial hemodynamic changes that stress the pulmonary circulation, including increased blood volume, cardiac output, and decreased systemic vascular resistance, which can unmask or worsen underlying pulmonary vascular disease 8, 9, 10, 11
• Maternal deaths typically occur in the last trimester or first months postpartum due to pulmonary hypertensive crises, thrombosis, or right heart failure, as noted by the European Heart Journal 8, 9, 10, 11

Measurement Considerations

• Right heart catheterization remains the gold standard for measuring mPAP, with the same normal values (14-20 mmHg) applying to pregnant and non-pregnant patients, according to the American College of Radiology 6, 7
• Echocardiography can estimate PA systolic pressure but is insufficient alone for treatment decisions regarding pulmonary hypertension therapy, as stated by the European Heart Journal 12

Key Clinical Pitfall

• Pregnancy is contraindicated (WHO class IV) in women with established pulmonary hypertension regardless of severity, given the high maternal mortality risk, as recommended by the European Heart Journal 13